avacopan (Tavneos) Report issue

Small molecule Orphan Drug FDA Approved FDA First in Class
AACT ChEMBL PubChem

Active Ingredient History

NOW
  • Now

Chemistry

  • SMILES: Cc1ccc(NC(=O)[C@H]2CCCN(C(=O)c3c(C)cccc3F)[C@H]2c2ccc(NC3CCCC3)cc2)cc1C(F)(F)F
  • InChIKey: PUKBOVABABRILL-YZNIXAGQSA-N
  • Mol. Mass: 581.65
  • ALogP: 8.05
  • ChEMBL Molecules:
    avacopan  
    None  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Oral
  • Pro Drug: No

Alternative names

ccx168 | ccx-168

Organizations (5)

Research & Development (5)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (11)

Approved Indications (3)


 

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis

Granulomatosis with Polyangiitis (approved 2021)

Microscopic Polyangiitis (approved 2021)

Experimental Indications - Clinical Trial Phases 1-4 (9)


 

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (Phase 3)

Atypical Hemolytic Uremic Syndrome (Phase 2)

Electrocardiography (Phase 1)

Glomerulonephritis, IGA (Phase 2)

Hidradenitis Suppurativa (Phase 2)

Kidney Diseases (Phase 2)

Liver Diseases (Phase 1)

Lupus Erythematosus, Systemic (Phase 1)

Vasculitis (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 15
  • # of Trial Organizations: 5

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue